Citius Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved its lymphoma drug LYMPHIR. This marks the first FDA approval for the drug developer. Despite this, quotes on Citius Pharmaceuticals shares plummeted 17% after the opening bell, followed by a slight rebound later. Earlier this week, Citius…